智通财经网·2026-03-30 15:39Core Viewpoint - Zhaoyan New Drug (603127.SH) reported a revenue of 1.658 billion yuan for the year 2025, reflecting a year-on-year decrease of 17.87% while achieving a net profit attributable to shareholders of 298 million yuan, which represents a significant year-on-year increase of 302.08% [1] Financial Performance - The company’s revenue for 2025 was 1.658 billion yuan, down 17.87% compared to the previous year [1] - The net profit attributable to shareholders reached 298 million yuan, marking a substantial increase of 302.08% year-on-year [1] - The net profit excluding non-recurring gains and losses was 311 million yuan, showing an impressive growth of 1221.30% year-on-year [1] - Basic earnings per share were reported at 0.40 yuan [1] Dividend Distribution - The company plans to distribute a cash dividend of 1.2 yuan (including tax) for every 10 shares to all shareholders [1] Business Segments - The net profit attributable to shareholders, excluding non-recurring gains and losses, was primarily driven by profits from laboratory services and other business operations, along with the impact of fluctuations in the market value of biological assets [1]